Once-Daily Cetirizine Is Safe and Effective for Children with Allergic Rhinitis with and without Intermittent Asthma

A. Segal, E. Meltzer, R. Lockey, B. Prenner, D. Q. Mitchell, D. Tinkelman, D. Hewlett, D. Chapman, B. Kramer
{"title":"Once-Daily Cetirizine Is Safe and Effective for Children with Allergic Rhinitis with and without Intermittent Asthma","authors":"A. Segal, E. Meltzer, R. Lockey, B. Prenner, D. Q. Mitchell, D. Tinkelman, D. Hewlett, D. Chapman, B. Kramer","doi":"10.1089/088318703322751318","DOIUrl":null,"url":null,"abstract":"The prevalence of seasonal allergic rhinitis among 1 to 12 year olds is between 10% and 20%. Cetirizine is a selective, once-daily H1 antagonist approved for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria in adults and children 2 years and older, and was recently approved for the treatment of perennial allergic rhinitis and chronic urticaria in children down to 6 months of age. This randomized, multicenter, double-blind, placebo-controlled study enrolled 172 children with seasonal allergic rhinitis, including a large subgroup with concomitant asthma. Cetirizine syrup or placebo were administered for 2 weeks. Cetirizine 10 mg once daily provided significant relief from symptoms of seasonal allergic rhinitis, both in children with and without concomitant asthma. Among subjects with asthma, the frequency and severity of asthma symptoms were similar between the cetirizine and placebo groups. Cetirizine caused no adverse effects on pulmonary function ...","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"10 1","pages":"265-274"},"PeriodicalIF":0.0000,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric asthma, allergy & immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/088318703322751318","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

The prevalence of seasonal allergic rhinitis among 1 to 12 year olds is between 10% and 20%. Cetirizine is a selective, once-daily H1 antagonist approved for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria in adults and children 2 years and older, and was recently approved for the treatment of perennial allergic rhinitis and chronic urticaria in children down to 6 months of age. This randomized, multicenter, double-blind, placebo-controlled study enrolled 172 children with seasonal allergic rhinitis, including a large subgroup with concomitant asthma. Cetirizine syrup or placebo were administered for 2 weeks. Cetirizine 10 mg once daily provided significant relief from symptoms of seasonal allergic rhinitis, both in children with and without concomitant asthma. Among subjects with asthma, the frequency and severity of asthma symptoms were similar between the cetirizine and placebo groups. Cetirizine caused no adverse effects on pulmonary function ...
每日一次西替利嗪对伴有或不伴有间歇性哮喘的变应性鼻炎儿童安全有效
1至12岁儿童中季节性变应性鼻炎的患病率在10%至20%之间。西替利嗪是一种选择性的、每日一次的H1拮抗剂,被批准用于治疗2岁及以上成人和儿童的季节性变应性鼻炎、常年性变应性鼻炎和慢性特发性荨麻疹,最近被批准用于治疗6个月以下儿童的常年性变应性鼻炎和慢性荨麻疹。这项随机、多中心、双盲、安慰剂对照的研究纳入了172名患有季节性变应性鼻炎的儿童,其中包括一个大的伴有哮喘的亚组。西替利嗪糖浆或安慰剂治疗2周。西替利嗪10mg每日1次可显著缓解季节性变应性鼻炎的症状,无论是否伴有哮喘。在哮喘患者中,西替利嗪组和安慰剂组哮喘症状的频率和严重程度相似。西替利嗪对肺功能无不良影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书